<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553553</url>
  </required_header>
  <id_info>
    <org_study_id>St. Vincent's Hospital Ireland</org_study_id>
    <nct_id>NCT00553553</nct_id>
  </id_info>
  <brief_title>Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery</brief_title>
  <acronym>RITM-IVM</acronym>
  <official_title>Efficacy Of IV Morphine vs Remifentanil-Intrathecal Morphine Analgesia During Hepatic Resection Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's University Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Vincent's University Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patient population requiring hepatic resection can demonstrate an unpredictable risk of
      exhibiting peri-operative coagulopathy resulting either from the pre-operative hepatic
      pathophysiology or volume of parenchymal resection. Choice of analgesia can be severely
      limited.

      Currently, the most commonly described use of combined remifentanil infusion and intrathecal
      morphine has been in fast-track cardiac surgery. To date, there are no published data
      describing its use in the context of major hepatobiliary where the investigators predict it
      may provide adequate analgesia with a lower rate of adverse effects over the first 24 hours
      after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choice of analgesia in hepatic resection surgery can be severely limited. This can depend
      upon on the pre-operative hepatic pathophysiology or the extent of parenchymal resection,
      both of which will affect peri-operative hepatic function, capacity for drug handling and
      risk of coagulopathy. Use of IV morphine during hepatic resection can result in high plasma
      levels post-operatively due to a reduced rate of morphine metabolism, risking a higher rate
      of morbidity. However, this remains a mainstay of peri-operative analgesia in combination
      with controversial non-opioid supplementation (paracetamol, non-steroidal anti-inflammatory
      drugs).

      This study compares the efficacy of IV morphine only versus a combination of pre-incisional
      intrathecal morphine and intra-operative IV remifentanil. Intrathecal morphine provides the
      mainstay of post-operative analgesia for 12-24 hours and remifentanil provides profound,
      titratable intra-operative analgesia until the delayed onset of the intrathecal morphine. We
      hypothesise that this combination might provide desirable intra-operative haemodynamic
      conditions and eliminate the post-operative additive effects of long-acting, intra-operative
      IV opioid and intrathecal morphine. Further, if the dose of intrathecal morphine is adequate,
      this would result in a low rate of post-operative analgesic supplementation and fewer side
      effects. The titratable dose range of remifentanil is limited to the lower range found to
      risk post-operative hyperalgesia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Anticipated">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid-related side effects</measure>
    <time_frame>First 24 hours post-operatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IV opioid analgesic supplementation</measure>
    <time_frame>First 24 hours post-operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Liver Dysfunction</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV morphine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil-intrathecal morphine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine sulphate</intervention_name>
    <description>Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine hydrochloride, remifentanil hydrochloride</intervention_name>
    <description>Pre-induction intrathecal morphine HCl (&lt; 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram
Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  ASA I, II or stable III

          -  Undergoing primary elective hepatic resection of &lt; 50% predicted parenchymal resection

        Exclusion Criteria:

          -  Previous major upper GI surgery:

               -  liver resection or transplant

               -  gastrectomy

               -  oesophagectomy

               -  Whipple's procedure

          -  Contraindications to dural puncture:

               -  coagulopathy

               -  uncorrected anti-coagulant therapy

               -  spinal deformity

               -  neurological disorder

               -  psychiatric disorder

          -  Morphine allergy

          -  Co-morbidity predisposing to failure of extubation at conclusion of surgery:

               -  severe cardiopulmonary pathology scoring ASA III (unstable)

               -  IV

               -  V

               -  sleep apnoea

               -  morbid obesity (BMI &gt; 35)

          -  Failure to proceed with resection, emergency resection or conversion to &gt; 50%
             parenchymal resection

          -  Chronic/intractable pain conditions:

               -  requiring long-term high dose analgesia

               -  implanted analgesic devices

          -  Predisposition to severe post-operative nausea and vomiting:

               -  motion sickness

               -  previous PONV

          -  Anatomical or physiological indication for rapid sequence induction (relative)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil J. McDonald, MB BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's University Hospital, Ireland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie A. D'Oyley, MB BS</last_name>
    <phone>+3531 2094262</phone>
    <email>doyleyda@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neil J. McDonald, MB BCh</last_name>
    <phone>+3531 2094262</phone>
    <email>n.mcdonald@svuh.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>County Dublin</state>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil J. McDonald, MB BCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <last_update_submitted>December 30, 2008</last_update_submitted>
  <last_update_submitted_qc>December 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. N. J. McDonald</name_title>
    <organization>St. Vincent's University Hospital, Dublin</organization>
  </responsible_party>
  <keyword>Intrathecal morphine ITM intravenous morphine remifentanil hepatic resection</keyword>
  <keyword>Adult</keyword>
  <keyword>ASA I-III (stable)</keyword>
  <keyword>Liver dysfunction requiring primary parenchymal resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

